1. Home
  2. Clinical Trials
  3. Pharmaceutical
  4. CDT : Clinical Studies (current)
scientific and microscope

Our clinical studies

We are committed to make our Clinical trials Information and Results accessible and transparent while maintaining participants privacy.

 

Clinical studies

This site provides information on both ongoing and completed clinical trials sponsored by Pierre Fabre since 2004. Real-world evidence studies which began after 01 January 2020 are also accessible.

 

Total studies

0

Current studies

0

Oncology

0

Dermatology

0

Rare diseases

0

Others

0
Show more filters
Title Therapeutic area Phase Status Start date Planned End date

Advanced breast cancer patients treated with oral vinorelbine: a prospective and retrospective, observational study – VINOREAL

 		Oncology RWE Active 03 May 2023 30 June 2028

A randomized, single-center, open-label, single dose, two-period, crossover pivotal bioequivalence study comparing binimetinib 3 x 15 mg and 45 mg tablets in healthy participants

 		Oncology Phase I Completed 31 August 2022 December 2022

Retrospective observational study of adult patients with early-stage HER-2 positive breast cancer, treated with neratinib as extended adjuvant therapy in the context of the European Early Access Program.

 		Oncology RWE Completed July 2022 July 2023

An observational study describing diagnosis and treatment patterns in adults with metastatic non-small cell lung cancer with BRAF V600E mutation in clinical practice, to assess treatment effectiveness and quality of life.

 		Oncology RWE Recruiting 23 June 2022 June 2025

Multicenter, Open-label, Phase II Study with a Safety Lead-in part Investigating the Efficacy, Safety and Pharmacokinetics of Encorafenib and Binimetinib Combination in BRAFV600E mutated Chinese Patients with Metastatic Non-Small Cell Lung Cancer who are BRAF- and MEK inhibitor treatment-naïve

 		Oncology Phase II Recruiting 02 June 2022 February 2025
1 - 5 over 17

Get access to Partner's pivotal studies supporting our authorized drugs in Europe

Results from pivotal studies conducted by our partners and supporting a marketing approval for whom Pierre Fabre is the holder in Europe are shared below:

 

Melanoma

Phase III  -  COLUMBUS

SPONSOR: PFIZER

Breast cancer 

Phase III    -    EXTENET

SPONSOR: PUMA BIOTECHNOLOGY

Colorectal cancer

Phase III - BEACON CRC

SPONSOR: PFIZER

Post-transplantation lymphoproliferative disease EBV+

Phase III     -       ALLELE

SPONSOR: ATARA